Skip to content

Physiologic Mechanisms in Pediatric Traumatic Brain Injury (TBI)

Physiologic Mechanisms in Pediatric Traumatic Brain Injury (TBI)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01763892
Enrollment
60
Registered
2013-01-09
Start date
2012-12-31
Completion date
2015-09-30
Last updated
2015-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Traumatic Brain Injury

Keywords

Pediatric, Traumatic Brain Injury, TBI, Apolipoprotein E, apo-E, Vasospasm, Genetics, Physiologic Mechanisms, Neurocognitive Outcomes, Endothelin 1

Brief summary

The aims of this study explore the relationships between cerebral vasospasm, apolipoprotein-E (apo-E) genotype, physiologic symptoms, and neurocognitive outcomes that may either intensify or ameliorate secondary injury, for children with a traumatic brain injury. Exploring the apo-E genotype will help us know if injury response is altered in certain children and will aid in developing interventional approaches.

Detailed description

The purpose of this study is to advance knowledge of neurocognitive outcomes in pediatric traumatic brain injury (TBI) patients by exploring the relationships between physiologic factors of cerebral vasospasm, apolipoprotein E (apo-E) allele, biomarkers, and neurocognitive outcomes. This study is a funded project within Duke University School of Nursing National Institutes of Health/National Institute of Nursing Research (NIH/NINR) P30 Center of Excellence Grant. This study will continue on with some of the work of a small intramural grant study determining the feasibility of conducting pediatric TBI research at DUHS. It will advance the measurement of vasospasm by translating the use of the Transcranial Doppler (TCD) ultrasound to neuromonitoring in children. To date, this will be the first pediatric study examining the relationship of cerebral vasospasm, apo-E, and biomarkers with neurocognitive outcomes. Unlike adult TBI patients, cerebral vasospasm, apo-E, and biomarker collections have yet to be examined in pediatric neurotrauma patients in the Duke University Health System. Although neurocognitive outcomes are a standard of care for TBI patients at Duke University Health System (DUHS), the data has yet to be examined within the realm of pediatric neurodiagnostic physiologic measures. By obtaining preliminary data in 35 patients, it will allow for the evaluation of multi-diagnostic measures in pediatric TBI patients, as well as provide data for future funding for a larger regionally-scale study.

Interventions

None listed

Sponsors

National Institute of Nursing Research (NINR)
CollaboratorNIH
Duke University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
5 Days to 15 Years
Healthy volunteers
No

Inclusion criteria

1. TBI patients admitted to the pediatric intensive care service (PICU)or pediatric progressive care unit 2. Range in age from birth to 15 years 3. TBI with a Glasgow Coma Scale of 3-15 4. Acoustic window for adequate transcranial doppler (TCD) ultrasound 5. English or Spanish speaking or understanding parent/legal guardian to consent 6. Access for a buccal swab for genotyping

Exclusion criteria

1. Non-English or Spanish speaking parents/legal guardian 2. Children with a previously diagnosed neurodevelopmental delay

Design outcomes

Primary

MeasureTime frameDescription
Presence of apolipoprotein E (apo-E) alleleDay 1Collection of Apo-E allele will be obtained by buccal swab upon enrollment

Secondary

MeasureTime frameDescription
Vasospasm detection by Transcranial Doppler Ultrasound (TCD)8 daysDaily Transcranial doppler ultrasound will performed in pediatric traumatic brain injury patients through hospital day 8. If vasospasm is present and persists beyond hospital day 8, daily TCD examinations will be continued until resolution of vasospasm is noted.

Other

MeasureTime frameDescription
Biomarker Detection5 daysDetection of a defined set of protein biomarkers from biological samples collected at baseline, 24, 48, and 96 hours.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026